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PENINGKATAN BIOKEPEROLEHAN ORAL DRUG-DRUG SUSAH 
LARUT DAN SUSAH TELAP MELALUI SISTEM PENGHANTARAN DRUG 
“PENGEMULSIAN-MIKROKENDIRI” DAN KESAN PIPERINE 
 
                                                           ABSTRAK 
 
Terdapat lebih kurang 40% molekul drug baru yang ditemui dan sebahagian melekul 
drug yang terdapat dalam pasaran, mempunyai bioperolehan yang rendah disebabkan 
oleh keterlarutan dan/atau ketelapan yang rendah. Kajian ini bertujuan menghasilkan 
suatu sistem penghantaran drug “pengemulsian-mikrokendiri” (SMEDDS) dengan 
menggunakan dua drug BCS Kelas IV, iaitu sulpiride dan norfloxacin. Sulpiride 
ialah substrat P-gp dan norfloxacin ialah substrat MRP2, BCRP dan suatu pam efluks 
yang tidak diketahui. Daripada kajian keterlarutan drug-drug dalam pelbagai minyak, 
surfaktan dan ko-surfaktan, asid oleik, Tween 80 dan propilena glikol, dipilih untuk 
menyediakan formulasi SMEDDS. Dua formulasi dipilih untuk kajian seterusnya 
berdasarkan pada saiz titisan dan keterlarutan. Formulasi pertama terdiri daripada 
4.76 % b/b asid oleik, 63.49% b/b Tween 80 dan 31.75% b/b propilena glikol, 
dengan diameter purata titisan 9.27 nm dan keterlarutan 22 mg/1000 mg untuk 
sulpiride, manakala 9.57 nm dan 17.33 mg/1000 mg untuk norfloxacin masing-
masing. Formulasi yang satu lagi terdiri daripada 17.71% b/b asid oleik, 55.14% b/b 
Tween 80 dan 27.15% b/b propilena glikol, dengan diameter purata titisan 85 nm dan 
keterlarutan drug 32 mg/1000 mg sulpiride, manakala 92 nm dan 27.53 mg/1000 mg 
untuk norfloxacin. Kaedah-kaedah isokratik HPLC-fluoresens yang ringkas, spesifik 
dan sensitif telah dibangunkan dan divalidasikan untuk menentukan kepekatan 
sulpiride dan norfloxacin dalam perfusat usus kecil tikus dan plasma arnab. 
Eksperimen ketelapan in situ dijalankan atas tiga bahagian usus kecil, duodenum, 
jejunum dan ileum tikus dengan teknik “single-pass perfusion”. Formulasi SMEDDS 
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dan larutan misel menunjukkan peningkatan signifikan dalam koefisi ketelapan 
berkesan drug melalui ketiga-tiga bahagian usus kecil, dibandingkan dengan larutan 
drug untuk kedua-dua drug. Tidak terdapat perbezaan signifikan nilai-nilai koefisi 
ketelapan berkesan antara formulasi SMEDDS dan larutan misel untuk kedua-dua 
drug. Apabila kesan saiz titisan atas ketelapan jejunum dikaji, didapati tidak ada 
perbezaan signifikan untuk nilai-nilai koefisi ketelapan dengan saiz titisan kurang 
daripada 100 nm. Daripada kajian bioperolehan in vivo arnab, didapati pengurangan 
signifikan Tmax dan peningkatan signifikan Cmax dan AUC formulasi SMEDDS 
apabila dibandingkan dengan Dogmatil®/Norfloxin®. Sebaliknya, kadar dan amaun 
sulpiride/norfloxacin diserap tidak dipengaruhi dengan signifikan, apabila saiz titisan 
kurang daripada 100 nm dibandingkan. Apabila kesan perasa piperine atas 
bioperolehan oral ampaian sulpiride/norfloxacin dan formulasi SMEDDS dinilai, 
didapati pengambilan bersama kedua-dua drug dengan piperine, dalam ampaian dan 
formulasi SMEDDS meningkatkan bioperolehan kedua-dua drug secara signifikan. 
Pengambilan bersama piperine dengan formulasi SMEDDS meningkatkan lagi 
bioperolehan drug. Maka, SMEDDS boleh digunakan untuk meningatkan 
biperolehan drug-drug yang susah larut dan susah telap.  
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ORAL BIOAVAILABILITY ENHANCEMENT OF POORLY SOLUBLE AND 
POORLY PERMEABLE DRUGS USING SELF-MICROEMULSIFYING 
DRUG DELIVERY SYSTEMS AND THE EFFECT OF PIPERINE 
 
ABSTRACT 
 
There are approximately 40% of new drug molecules discovered and some drug 
molecules that are available in the market, having poor bioavailability due to poor 
solubility and/or poor permeability. The present study aimed at formulating a self-
microemulsifying drug delivery system (SMEDDS) using two BCS class IV drugs, 
namely sulpiride and norfloxacin. Sulpiride is a P-gp substrate and norfloxacin is a 
substrate of MRP2, BCRP and an unknown efflux pump. From the solubility studies 
of drugs in various oils, surfactants and co-surfactants, oleic acid, Tween 80 and 
propylene glycol were chosen to prepare SMEDDS formulations. Two formulations 
were chosen for further study based on droplet size and solubility. The first 
formulation consisted of 4.76% w/w of oleic acid, 63.49% w/w of Tween 80 and 
31.75% w/w of propylene glycol, with a mean droplet diameter of 9.27 nm and drug 
solubility of 22 mg/1000 mg for sulpiride, 9.57 nm and 17.33 mg/1000 mg for 
norfloxacin respectively. The other formulation consisted of 17.71% w/w of oleic 
acid, 55.14% w/w of Tween 80 and 27.15% w/w of propylene glycol, with a mean 
droplet diameter of 85 nm and drug solubility of 32 mg/1000 mg for sulpiride, 92 nm 
and 27.53 mg/1000 mg for norfloxacin. Isocratic HPLC- fluorescence methods were 
developed and validated for the determination of sulpiride and norfloxacin in rat 
intestinal perfusates and rabbit plasma separately. The in situ permeability 
experiment was performed on three intestinal segments, duodenum, jejunum and 
ileum in rats using single-pass perfusion technique. The SMEDDS formulation and 
micellar solution exhibited significant increase in the effective permeability 
 xxxix
coefficient of the drug across all the three intestinal segments compared with drug 
solution for the two drugs. There was no significant difference in the effective 
permeability coefficients values between SMEDDS formulation and micellar 
solution for both drugs. When the effect of droplet sizes on jejunum permeability 
was studied, it was found that there was no significant difference in permeability 
coefficients with droplet sizes of less than 100 nm. From the in vivo bioavailability 
study performed in rabbits, it was found that there was a significant decrease in the 
Tmax and significant increase in the Cmax and AUC of the SMEDDS formulations 
when compared with Dogmatil®/Norfloxin® respectively. On the other hand, the rate 
and extent of absorption of sulpiride/norfloxacin were not significantly affected, 
when the droplet sizes of less than 100 nm were compared. When the effect of 
dietary spice piperine on the oral bioavailability of sulpiride/norfloxacin suspension 
and SMEDDS formulations was evaluated, it was found that concomitant 
administration of both the drugs with piperine in suspension and SMEDDS 
formulations significantly enhanced the oral bioavailability of these two drugs. 
Concomitant administration of piperine with SMEDDS formulation further increased 
the bioavailability of the drugs. Hence, SMEDDS can be used to increase the 
bioavailability of poorly soluble and poorly permeable drugs.  
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Chapter 1 
Introduction 
 
1.1 Oral drug delivery 
The predominant way to deliver drugs to the systemic circulation to generate 
pharmacological and clinical effects is the oral route. The oral route is easily 
accessible with minimum discomfort to patients, in comparison with other routes of 
drug administration. The design and composition of the pharmaceutical dosage form 
as well as the physico-chemical properties of the drug itself affect the in vivo 
performance and hence the therapeutic outcome (Petri and Lennernas, 2003).  
 
The rate and extent of absorption of drugs following oral administration is governed 
by several factors. As the drug passes down the gastrointestinal tract, part of the dose 
may not be available for absorption owing to poor aqueous solubility, limited 
membrane permeability, and/or chemical or biological degradation. Drug molecules 
absorbed into the intestinal membranes can then be further subject to intestinal 
and/or hepatic first pass elimination before reaching the systemic circulation. A 
thorough understanding of the quantitative contributions of the two processes, 
solubility and permeability, during absorption is important for enhancing the oral 
bioavailability of drugs. 
 
1.2 Biopharmaceutic Classification System (BCS) 
In view of the importance of solubility and permeability on the oral bioavailability of 
drugs, USFDA has introduced the Biopharmaceutic Classification System (BCS), a 
scientific framework for classifying drug substances based on their dissolution rate, 
aqueous solubility, and intestinal permeability (Amidon et al., 1995; Yu et al., 2002). 
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According to BCS, drug substances are classified as follows (The Biopharmaceutic 
Classification System Guidance, USFDA): 
 
Class I - High Permeability, High Solubility 
Class II - High Permeability, Low Solubility 
Class III - Low Permeability, High Solubility 
Class IV - Low Permeability, Low Solubility 
 
The class boundaries are set based on the following criteria:- 
¾ A drug substance is considered HIGHLY SOLUBLE when the highest dose 
strength is soluble in < 250 ml water over a pH range of 1 to 7.5. 
¾ A drug substance is considered HIGHLY PERMEABLE when the extent of 
absorption in human is determined to be > 90% of an administered dose, 
based on mass-balance or in comparison with an intravenous reference dose. 
¾ A drug product is considered to be RAPIDLY DISSOLVING when > 85% of 
the labeled amount of drug substance dissolves within 30 min using USP 
apparatus I or II in a volume of < 900 ml buffer solutions (Yu et al., 2002).  
 
Class I drugs behave like an oral solution having fast dissolution and rapid 
bioavailability. Since the dissolution and absorption of these drugs is very fast, 
bioavailability and bioequivalence studies are not necessary for the products that 
contain these drugs. The drugs belonging to this class are good candidates for 
controlled drug delivery if they have suitable pharmacokinetic and pharmacodynamic 
attributes.  
 
Drugs belonging to Class II have low solubility and high permeability. Hence, the 
dissolution rate becomes the governing parameter for bioavailability. The drugs 
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belonging to this class may exhibit poor oral bioavailability. Various formulation 
techniques have been reported to enhance the dissolution rate and the bioavailability 
of this class of drug molecules.  
 
For drugs belonging to Class III, permeation through the intestinal membranes forms 
the rate-determining step for bioavailability. The drug release from the dosage form 
and the dissolution rate do not influence the bioavailability of such drugs. Generally, 
these drugs exhibit low oral bioavailability. Different permeability enhancement 
techniques have been developed to enhance the bioavailability of this class of drugs. 
Drugs belonging to this class exhibit poor and variable bioavailability.  
 
 
The oral bioavailability of Class IV is governed by solubility and permeability. These 
drugs are not generally suitable for oral administration and special drug delivery 
technologies are required to make them suitable for oral administration. A 
combination of techniques used for Class II and Class III drugs can be used to 
enhance the solubility and permeability and hence the bioavailability of these drugs 
(Ku, 2008).  
 
1.3 Techniques to enhance solubility or dissolution rate of poorly soluble drugs 
Drugs with poor aqueous solubility (BCS Class II and IV) show in vivo performance 
limitations, such as incomplete or erratic absorption and poor bioavailability. The 
effectiveness can vary from patient to patient, and there can be a strong effect of food 
on drug absorption. To overcome the in vivo performance limitations with BCS class 
II and class IV drugs, various formulation techniques have been developed to 
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enhance the solubility and dissolution rate of these drugs and their oral 
bioavailability. These formulation techniques are elaborated below. 
 
1.3.1 Adjustment of pH and use of co-solvent  
For drug molecules that are ionizable, changing the pH of the system may be the 
simplest and most effective means of increasing aqueous solubility. Under the proper 
conditions, the solubility of an ionizable drug can increase exponentially by adjusting 
the pH of the solution. A drug that can be efficiently solubilized by pH control 
should be either weak acid or a weak base. There is little effect of pH on unionizable 
substances (Tong, 2008). Unionizable, hydrophobic substances can have improved 
solubility by changing the dielectric constant of the solvent by the use of co-solvents 
rather than the pH of the solvent. Water miscible solvents with intermediate 
dielectric constant values, like propylene glycol, polyethylene glycols, glycerin and 
alcohol are generally used as co-solvents in the preparation of oral dosage forms of 
poorly soluble drug substances (Seedher and Bhatia, 2003). 
 
1.3.2 Salt form of the drug 
Salts of acidic and basic drugs have, in general, higher solubilities than their 
corresponding acid or base forms. Salt formation to increase aqueous solubility is the 
most preferred approach for the development of liquid formulations for parenteral 
administration (Sweetana and Akers, 1996). For solid dosage forms, Nelson (1957, 
1958) demonstrated that dissolution rates of salt forms of several weakly acidic 
compounds under gastrointestinal pH conditions were higher than those of their 
respective free acid forms. He attributed the higher dissolution rate of a salt to its 
higher solubility (relative to the free acid form) in the aqueous diffusion layer 
surrounding the solid. There was a significant increase in the rate and extent of 
 4
absorption of novobiocin and tolbutamide in salt form compared to their respective 
base (Furesz, 1958; Nelson et al., 1962). This method is not applicable to extremely 
water-insoluble drugs. Salts may precipitate out in the gastrointestinal fluid after oral 
administration, into their free acid and base forms. For extremely insoluble drugs, the 
precipitates may not redissolve rapidly due to their very low aqueous solubilities 
(Serajuddin, 2007). 
 
1.3.3 Particle size reduction 
Particle size reduction can enhance the dissolution rate of drugs. By reducing the 
particle size, the increased surface area increases the dissolution of the drug. 
Conventional methods of particle size reduction, such as comminution and spray 
drying, rely upon mechanical stress to disaggregate the active compound. 
Micronization is used to increase the specific surface area for dissolution. 
Micronization of drugs by conventional methods is carried out by milling techniques 
using jet mill, rotor stator and colloid mills. Spray drying is a commonly used 
particle size reduction method. In this method, hot nitrogen gas is used to dry the 
liquid feed of the drug. The liquid feed may be a solution, colloidal dispersion or 
suspension of the drug. The basic principle involved in the process of spray drying is 
the liquid feed is passed through a nozzle. Spray drying of the salicylic acid 
dispersed in acacia solutions resulted in as much as a 50% improvement in the 
solubility of poorly water soluble salicylic acid (Kawashima et al., 1975). 
 
The micronization of drug powders to sizes between 1 and 10 μm to increase the 
surface area, and thus the dissolution velocity, is not sufficient to overcome 
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bioavailability problems of many very poorly soluble drugs. A consequent step was 
to move from micronization to nanonization (Keck and Muller, 2006). 
 
Nanonization is one of the most promising techniques to improve the oral 
bioavailability of poorly soluble drugs by increasing the surface area and saturation 
solubility via reduction of the particle size to less than 1μm. Such size reduction 
cannot be achieved by the conventional milling techniques. The various technologies 
that have emerged to decrease the particle size to nanosize include pearl milling 
(Nano Crystals®) ((Bhupendra et al., 2007; Junghanns and Muller, 2008), 
homogenization techniques (IDD-P™ technology) (Junghanns and Muller, 2008), 
DissoCubes® technology (Junghanns and Muller, 2008), Nanopure® technology 
(Bushrab and Muller, 2003), supercritical fluid technology (Byrappa et al., 2008), 
spray freezing into liquid (Vaughn et al., 2006) and evaporative precipitation into 
aqueous solution (Vaughn et al., 2005).  
 
1.3.4 Polymorphic modification (polymorphs) 
Polymorphism is the ability of a compound to crystallize in more than one crystalline 
form. Different polymorphs of drugs are chemically identical, but they exhibit 
different physicochemical properties and biological activities including solubility, 
melting point, density, texture, stability and bioavailability. With regard to 
bioavailability, it is preferable to change drug from stable crystal forms into 
metastable or amorphous forms. Nonetheless, there have been numerous reports 
demonstrating the influence of polymorphic and crystalline form on dissolution rate 
and/or oral bioavailability. Metastable forms of phenobarbital, spironolactone and 
carbamazepine provided enhanced dissolution behaviour compared to the other 
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polymorphs of the respective drugs (Κato et al., 1984; Salole and Al-Sarraj, 1985; 
Kobayashi et al., 2000). Singhal and Curatolo (2004) reviewed a number of 
examples showing differences in pharmacokinetic profiles in human subjects relating 
to batch to batch variations in the polymorphic forms of carbamazepine and 
oxytetracycline. Although the utilisation of metastable polymorphs offers improved 
dissolution and oral bioavailability, concern still exists with respect to conversion of 
these materials to more stable crystalline forms during processing and storage. It is 
therefore preferable to develop the most thermodynamically stable polymorph of the 
drug to assure reproducible bioavailability of the product over its shelf-life under a 
variety of real-world storage conditions. For instance, ritonavir is the active 
ingredient in Norvir®, a protease inhibitor used to treat HIV/AIDS. It was launched 
by Abbott Laboratories in 1996, as an amorphous semisolid dispersion consisting of 
medium chain triglycerides, polyoxyl 35 castor oil, citric acid, ethanol, 
polyglycolyzed glycerides, polysorbate 80, propylene glycol and 100 mg of ritonavir. 
The dissolution and the oral bioavailability were decreased due to crystallization of 
amorphous ritonavir into an insoluble crystal form during storage. This polymorph 
(form II) was 50% less soluble than the original form in the market, and caused the 
drug to fail its regulatory dissolution specifications. Finally, the drug was relaunched 
with the form II polymorph in a soft gelatin formulation that required refrigeration 
(Datta and Grant, 2004). Therefore, it is important to note that the selection of a 
polymorph of a drug should balance between solubility and stability to maintain its 
potency over the shelf-life period. 
 
 
Generally, the anhydrous form of a drug has a greater solubility than the hydrates. 
This is because the hydrates are already in interaction with water and therefore have 
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less energy for crystal breakup in comparison to the anhydrates (i.e. 
thermodynamically higher energy state) for further interaction with water. On the 
other hand, the organic (nonaqueous) solvates have greater solubility than the 
nonsolvates. Glibenclamide has been isolated as pentanol and toluene solvates, and 
these solvates exhibit higher solubility and dissolution rate than two non-solvated 
polymorphs (Suleiman and Najib, 1989). 
 
 
1.3.5 Complexation 
Cyclodextrins (CD) and their derivatives have been employed as complexing agents 
for enhancement of solubility, dissolution rate and bioavailability of drugs. 
Cyclodextrin inclusion is a molecular phenomenon in which usually only one guest 
molecule interacts with the cavity of a cyclodextrin molecule to become entrapped 
and form a stable association. The internal surface of cavity is hydrophobic and 
external is hydrophilic. Molecules or functional groups of molecules which are less 
hydrophilic than water can be included in the cyclodextrin cavity in the presence of 
water. In order to become complex, the "guest molecules" should fit into the 
cyclodextrin cavity. The cavity size as well as possible chemical modifications 
determine the affinity of cyclodextrins to the various molecules. Three naturally 
occurring CDs are α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin, are available. 
Various other cyclodextrins with better properties have been developed, for instance 
hydroxypropyl β-cyclodextrin. It was found that cyclodextrins increased paclitaxel 
solubility by 950 folds (Singla et al., 2002). Complex formation of norfloxacin 
(Guyot et al., 1995), clofibrate (Anguiano-Igea et al., 1996), taxol (Dordunoo and 
Burt, 1996), cyclosporine A (Ran et al., 2001) and rofecoxib (Baboota et al., 2005) 
with cyclodextrins improved the solubility and dissolution rate of these drugs. 
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1.3.6 Solid dispersions 
Solid dispersions are a eutectic mixture of drugs with water-soluble carriers formed 
by the melting of their physical mixtures (Serajuddin, 1999). Sekiguchi and Obi 
(1961) reported that the drug was present in a eutectic mixture in a microcrystalline 
state. Later, Goldberg et al. (1996) reported that drugs present in solid dispersions 
might not necessarily be present in microcrystalline state as certain fraction of the 
drug might be molecularly dispersed in the matrix, thereby forming a solid solution. 
In either case, once the solid dispersion was exposed to aqueous media and the 
carrier dissolved, the drug was released as very fine, colloidal particles. Because of 
greatly enhanced surface area obtained, the dissolution rate and the bioavailability of 
poorly water-soluble drugs were expected to be high. Solid dispersions are generally 
prepared either by melt technique or solvent evaporation technique. 
 
 
Although the solid dispersion technology has been developed in the early 1960’s, 
their commercial use has been very limited, primarily because of some limitations. 
These include method of preparation, reproducibility of its physicochemical 
properties, its formulation into dosage forms, the scale-up of manufacturing 
processes, and the physical and chemical stabilities of drug and vehicle. Only two 
products, griseofulvin-in polyethylene glycol solid dispersion (Gris-PEG®, Novartis) 
and nabilone-in-povidone solid dispersion (Cesamet®, Lilly) were marketed after 
three decades following the initial work of Sekiguchi and Obi in 1961 (Serajuddin, 
1999). 
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1.3.7 Lipid based drug delivery systems  
Lipid-based delivery systems range from simple oil solutions to complex mixtures of 
oils, surfactants and co-surfactants/co-solvents. The latter mixtures are typically self-
dispersing systems often referred to as self-emulsifying drug delivery systems 
(SEDDS) or self-microemulsifying drug delivery systems (SMEDDS) (Pouton, 
2006). 
 
Lipid Formulation Classification System (LFCS) was introduced as a working model 
in 2000 (Pouton, 2000), and an additional ‘type’ of formulation was included in 2006 
(Pouton, 2006). The main purpose of the LFCS is to enable in vivo studies to be 
interpreted more readily. The LFCS is shown in Table 1.1, with advantages and 
disadvantages of each system (Pouton and Porter, 2008). 
 
There are a few marketed preparations based on lipid based drug delivery. Many of 
the marketed lipid based products are Type III systems, but this group is particularly 
diverse as a result of the wide variation in the proportions of oily and water-soluble 
materials used. Considering this issue, this group has been further divided into Type 
IIIA and Type IIIB to distinguish between formulations which contain a significant 
proportion of oils (greater than 20% of oil) (Type IIIA) and those which are 
predominantly water-soluble substances (less than 20% of oil) (Type IIIB) (Pouton, 
2000; Pouton, 2006).  
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Table 1.1:    The Lipid Formulation Classification System: characteristic features, advantages and disadvantages of the four essential types of 
‘lipid’ formulations (Pouton and Porter, 2008). 
Formulation 
type Materials Characteristics Advantages Disadvantages 
Type I 
Oils without surfactants 
(e.g. tri, di-and 
monoglycerides) 
Non-dispersing, requires digestion 
Simple; excellent capsule 
compatibility 
Formulation has poor solvent 
capacity unless drug is highly 
lipophilic 
Type II 
Oils and water-insoluble 
surfactants 
SEDDS formed without water- 
soluble components 
Unlikely to lose solvent 
capacity on dispersion 
Turbid o/w dispersion (particle 
size 0.25-2 μm) 
Type III 
Oils, surfactants, co-
solvents 
SEDDS/SMEDDS formed with 
water-soluble components 
Clear or almost clear 
dispersion; drug absorption 
without digestion 
Possible loss of solvent 
capacity on dispersion; less 
easily digested 
Type IV 
Water-soluble surfactants 
and co-solvents (no oils) 
Formulation disperses typically to 
form a micellar solution 
Formulation has good solvent 
capacity for many drugs 
Likely loss of solvent capacity 
on dispersion; may not be 
digestible 
1.3.7 (a) Formulation of Type I systems 
This formulation system is without a surfactant and contains only lipophilic oils 
which have little or no water solubility. Typically, they contain vegetable oils which 
are rapidly digested and completely absorbed from the intestine. As these systems are 
prepared without the incorporation of surfactants, they depend on digestion to 
facilitate colloidal dispersion by solubilization of digestion products in mixed 
micelles. Both long chain triglycerides (LCT) and medium chain triglycerides (MCT) 
are digested by pancreatic enzymes when they enter the gastrointestinal tract (Porter 
et al., 2007).  The in vitro lipolysis experiments revealed that there are differences in 
the processing of the digestion products, which are likely to have effects on the fate 
of drugs in the intestinal lumen. Bile produced is not generally required for digestion 
of MCT, whereas bile is very essential for digestion of LCT. MCT of C8 and C10 
fatty acids and monoglycerides can exist as separate dispersed or dissolved phases 
(MacGregor et al., 1997). The LCT digestion products remain extensively solubilised 
within mixed bile salt–lecithin micelles until they are absorbed. The swollen mixed 
micelles formed by LCT digestion products are good solubilising systems for many 
drugs (MacGregor et al., 1997; Kossena et al., 2003; Kossena et al., 2004). 
Generally, the digestive products of MCT are absorbed through systemic circulation 
whereas those of the LCT through lymphatic system (Porter et al., 2007).  
 
1.3.7 (b) Formulation of Type II systems 
These formulations are formulated using oils and water insoluble surfactants. Typical 
formulations are mixtures of MCT oil and polysorbate 85 (Pouton, 1997) or mixtures 
of MCT oil and Tagat TO® (surfactant) (Wakerly et al., 1986). Self-emulsifying 
systems are formed when the surfactant concentration exceeds 25%w/w, the 
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optimum concentration range being 30–40% surfactant. Above 50% of surfactant, 
these systems emulsify slowly due to the formation of viscous liquid crystalline 
phases at the oil-water interface (Pouton, 2006). A Type II system was evaluated in 
dog (Charman et al., 1992) but since then these systems received limited attention 
and no marketed products have emerged.  
 
1.3.7 (c) Formulation of Type III systems 
Sandimmun Neoral® (Cyclosporine A) is a Type IIIA formulation, a 
SEDDS/SMEDDS formulation containing water-soluble surfactant and a significant 
mass of lipid components (Pouton, 2006). These formulations have the potential to 
disperse quickly to form fine submicron dispersions, often fine enough to form 
transparent dispersions. The Type IIIB formulation, which contains less than 20% of 
total weight of oil and high amount of water soluble substances, may fail to maintain 
the drug in a solubilized state.  Nevertheless, acyclovir (Patel and Sawant, 2007) and 
tacrolimus (Borhade et al., 2008) SMEDDS formulations were stable for more than 
24 hr after dilutions, when prepared as type IIIB formulation.  
 
1.3.7 (d) Formulation of Type IV systems 
These systems contain pure surfactants or mixtures of surfactants and cosolvents. It 
is generally accepted that formulation of poorly water-soluble drugs in pure 
cosolvents is likely to result in precipitation of the drug. The only advantage that 
could be gained is the possibility that the drug precipitates as a suspension of very 
fine crystalline or amorphous particles. Reliability is likely to be a problem with this 
strategy. Formulation of the drug in pure water-soluble surfactant makes more sense 
with regard to the aim of avoiding precipitation, since loss of solvent capacity is less 
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significant. There are two problems with using pure surfactants. The first is that 
surfactants often take a considerable time to dissolve, due to the formation of viscous 
liquid crystalline phases at the surfactant-water interface. The second is that pure 
surfactants can be irritant and poorly tolerated in the gastrointestinal tract. The 
amprenavir capsule formulation (Agenerase®, GSK) is a type IV formulation, a blend 
of tocopheryl polyethylene glycol 1000 succinate, PEG 400 and propylene glycol 
(Pouton, 2006; Pouton and Porter, 2008). 
 
1.4 Permeability 
The gastrointestinal (GI) tract morphology varies greatly from relatively no folding 
in the esophagus to high degrees of folding in the small intestine (Tortora and 
Grabowski, 1993). The villous epithelium of the small intestine acts as a primary 
barrier to GI absorption of drugs. The cells that mediate drug absorption across the 
intestinal villi are the polarized columnar enterocytes, which are eminent by the 
presence of apical membrane microvilli. The villi and the microvilli provide a 
significant increase in the intestinal absorptive surface area (Tortora and Grabowski, 
1993). Nevertheless, the compound’s physicochemical properties will dictate the 
pathway and extent of absorption. 
 
Paracellular and transcellular diffusion are the two routes of GI permeation (Adson et 
al., 1995). Paracellular permeation occurs by the diffusion of dissolved solute 
between cells through the tight junctions and tortuous pathway in the intercellular 
spacing (Adson et al., 1995; Knipp et al., 1997). The paracellular pathway is 
generally more restrictive. There are several physicochemical characteristics of a 
drug molecule that would favor paracellular diffusion including charge, 
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hydrophilicity, shape/conformation, size, and molecular weight (Adson et al., 1995; 
Knipp et al., 1997). 
 
The transcellular route is comprised of several potential parallel pathways for drug 
permeation including passive transcellular diffusion, ion channels, facilitated 
diffusion, active transport, and endocytosis (Oh and Amidon, 1999).  
 
In the past, the pH-partition hypothesis, first postulated in the mid to early 1900s, 
was used for predicting the absorption and/or disposition of a drug across biological 
membranes based on the octanol to aqueous partition coefficients as a function of 
ionization of the drug molecule (Jacobs, 1940). However, this method was 
inconsistent as many drugs deviated from the hypothesis (Higuchi and Davis, 1970). 
To overcome this problem, “The Rule of Five” was proposed by Lipinski et al. 
(1997; 2000; 2001) to estimate the permeability of compounds in silico based on 
molecular descriptors at the early stages of drug discovery. Lipinski’s Rule of Five 
states: “poor absorption or permeability is more likely when there are more than 5 H-
bond donors, 10 H-bond acceptors, the molecular weight is greater than 500 and the 
calculated log P is greater than 5.” (Lipinski et al., 1997). The main drawback of 
these techniques was that they never consider the role of drug transporters, in the 
overall absorption process. The Caco2 cell lines and in situ single-pass perfusion 
method were developed to overcome the problems faced with in silico techniques. 
However, all these techniques also have advantages and disadvantages. 
 
The complex nature of the intestine and the process of absorption as a whole 
relentlessly make the research regarding absorption process more challenging. The 
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lack of comprehensive predictive absorption methodologies is better understood 
when one considers the numerous roles elucidated for different drug transporters in 
mediating transcellular influx and efflux of xenobiotics. There are numerous classes 
of transporter proteins that have been identified, each with different and sometimes 
overlapping, substrate specificity, capacity and affinity, as well as specific tissue, 
cellular and temporal expression patterns. Transporter proteins are integral proteins 
of the membranes that function via either a facilitated diffusion, or active, energy-
dependent mechanisms to mediate transcellular flux of xenobiotics and nutrients (Oh 
and Amidon, 1999). A compound’s physicochemical properties greatly influence its 
interactions with transporters and lipophilic character (i.e., partitioning) plays a 
major role in determining these interactions (Stewart et al., 1997; Ekins et al., 2000; 
Kimura et al., 2002; Van DeWaterbeemd, 2002; Harrison et al., 2004; Kassel, 2004; 
Sun et al., 2004; Ekins et al., 2005). Enzymes of the Cytochrome P3A (CYP3A) 
family are predominant phase I drug metabolizing species found in human, 
accounting for approximately 30% of hepatic CYP (Shimada et al., 1994) and greater 
than 70% of small intestine CYP (Watkins et al., 1987; Zhang et al., 1999). So, along 
with efflux pumps the CYP3A is also a significant factor that needs to be addressed. 
The various influx and efflux transporters are presented in Fig 1.1. 
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Fig 1.1: Few of the influx and efflux drug transporters that affect the intestinal 
transport of drugs and their metabolites across intestinal epithelial 
membranes in humans. P-gp: P-glycoprotein; BCRP: Breast Cancer 
Resistant Protein; LRP: Lung Resistant Protein; MRP: Multi Drug Resistant 
Protein family; hPepT1: oligopepetide carrier for di and tripeptides; MCT: 
Monocarboxylic acid Co-Transporter. CYP3A4: Cytochrome P3A4 
enzyme. (Adapted from Petri and Lennernas, 2003). 
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1.4.1 ATP Binding Cassette transporters 
Several members of the ATP Binding Cassette (ABC) transporter protein have been 
reported to impart multidrug resistance by their ability to efflux xenobiotics from the 
cytoplasm and across the cellular membrane in an energy-dependent, polarized 
manner. A common characteristic shared by ABC transporters is the presence of 
nucleotide binding domain(s), which enable these integral membrane proteins to 
hydrolyze ATP to drive efflux (Higgins, 1991). Forty nine human ABC transporter 
isoforms have been identified. These again were separated into seven distinct 
subfamilies based on their sequence homology (ABCA to ABCG). Among these 
subfamilies, the ABCB and ABCC subfamilies contain the most widely investigated 
transporters influencing human intestinal absorption. Specifically, P-glycoprotein 
(ABCB1, P-gp) and multidrug resistance associated proteins (ABCC, MRP) have not 
only been shown to be expressed along the GI tract, but due to their cellular 
localizations and broad substrate specificities, appear to be the primary efflux pumps 
determining xenobiotic absorption. The ABCG2 isoform, also known as the breast 
cancer resistance protein (BCRP), has also been demonstrated to affect the intestinal 
absorption of various therapeutic agents.  
 
1.4.1 (a) P-glycoprotein (P-gp; ABCB1) 
P-gp is a 170-180 kDa, ATP-dependent transmembrane glycoprotein, which is 
formed by the post translational glycosylation of a 140 kDa pro-P-gp protein 
(Kramer et al., 1995). P-gp is comprised of four major domains; two membrane-
bound domains, each with six transmembrane segments and two cytosolic ATP 
binding motifs, that bind and hydrolyze ATP (Leveille-Webster and Arias, 1995). 
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Xenobiotics bind to separate sites on P-gp, indicating that different drugs can 
independently regulate P-gp function (Leveille-Webster and Arias, 1995). 
 
P-gp is localized to the apical brush-border membrane of the intestinal epithelium 
(Thiebaut et al., 1987). Due to the localized expression of P-gp at the apical side of 
brush border cells (Terao et al., 1996), P-gp limits the absorption of compounds by 
directly effluxing them back into the intestinal lumen. The level of P-gp expression 
increases from proximal to distal regions of the intestine (Mouly and Paine, 2003). P-
gp expression has also been reported in kidney, adrenal gland, liver, colon, apical 
membrane of the placenta, T lymphocytes and natural killer cells, blood-tissue 
barrier and lungs (Fojo et al., 1987; Sugawara et al., 1988; Thiebaut et al., 1989; 
Chaudhary and Roninson, 1991; Drenou et al., 1993; Gatmaitan and Arias, 1993). 
Low-level P-gp is also expressed in prostate, skin, spleen, heart, skeletal muscle, 
stomach, and ovary (Fojo et al., 1987; Gatmaitan and Arias, 1993). 
 
Two hypotheses have been postulated, namely, the “hydrophobic vacuum cleaner” 
(HVC) and the “flippase model” (FM), to explain the mechanism by which P-gp 
actively effluxes xenobiotics. The HVC model suggests P-gp clears substrates before 
they enter the cytoplasm (Higgins and Gottesman, 1992; Gottesman and Pastan, 
1993). Alternatively, the FM proposes that P-gp interacts with the xenobiotics as 
they enter through the lipid membrane and “flips” the drug from the inner leaflet to 
the outer leaflet and back into the extracellular media. Some of the P-gp substrates 
that have been identified are sulpiride (Baluom et al., 2001), digoxin (Anderle et al., 
2004), and paclitaxel (Yang et al., 2004). In contrast, some of the inhibitors of P-gp 
include quinidine, verapamil, cyclosporine A (Watanbe et al., 2004) and a few 
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pharmaceutical excipients like Tween 80, Cremophor EL, and polyethylene glycols 
(Hugger et al., 2002). 
 
1.4.1 (b) Multidrug Resistance-Associated Protein Family (MRP; ABCC) 
The human MRP gene encodes an MRP polypeptide with an apparent mass of 170 
kDa, which is post translationally converted to a 190 kDa form by the addition of N-
linked complex oligosaccharides (Almquist et al., 1995). Nine members within the 
MRP family have been identified, named as MRP1 to MRP6 (ABCC1 to ABCC6) 
and MRP7 to MRP9 (ABCC10 to ABCC12) (Belinsky et al., 1998; Bera et al., 2001; 
Kubota et al., 2001; Bera et al., 2002; Kruh and Belinsky, 2003).  
 
MRP1 is expressed on the basolateral side of the membrane; therefore its substrates 
are transported towards basolateral side of the epithelium (Evers et al., 1996). MRP2 
is expressed on apical side of the membranes (Evers et al., 1996). MRP2 is found in 
hepatocytes, in the luminal membrane of the small intestine and proximal tubules of 
the kidney (Schaub et al., 1997; Schaub et al., 1999; Mottino et al., 2000; Van Aubel 
et al., 2000). In human jejunum, MRP2 are amongst the highest expressed of all 
tested ABC transporters. MRP3 is expressed in liver, small and large intestine, 
adrenal gland, and to a lower extent in pancreas and kidney (Kool et al., 1997; 
Kiuchi et al., 1998; Scheffer et al., 2002). Lee et al. (2000) reported that MRP4 is 
localized to the human basolateral membrane of prostate. In contrast, Van Aubel et 
al. (2002) found human and rat MRP4 primarily in the apical side of brush border 
membrane of proximal tubular cells in the kidney. MRP4 is also expressed in several 
other tissues including jejunum, brain, lung, and gall bladder (Kool et al., 1997; 
Zhang et al., 2000; Taipalensuu et al., 2001; Van Aubel et al., 2002). The highest 
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expression of MRP5 is found in basolateral membranes of brain and skeletal muscle 
(McAleer et al., 1999). MRP5 is also present in basolateral erythrocyte membranes, 
colon, liver and kidney (Kool et al., 1997; McAleer et al., 1999; Jedlitschky et al., 
2000; Zhang et al., 2000). MRP6 is highly expressed in the kidney and liver, with 
low expression in several other tissues, like duodenum, colon, brain, and salivary 
gland (Zhang et al., 2000). Not much is known about MRP7, MRP8, and MRP9, 
although they are gaining increasing attention due to their involvement in conveying 
multidrug resistance (Bera et al. 2002; Kruh and Belinsky, 2003; Hopper-Borge et 
al., 2004; Chen et al., 2005).  
 
A few substrates of MRP1 are anthracyclines, vinca alkaloids, and camptothecin 
(Cole et al., 1994; Konig et al., 1999; Kruh and Belinsky, 2003). Inhibitors of MRP1 
are verapamil and its analogs (Cole et al., 1994).  
 
The glucuronide conjugates of bilirubin, estradiol, acetaminophen, grepafloxacin, 
triiodo-L-thyronine, and SN-38 are few of the MRP2 substrates identified (Suzuki 
and Sugiyama, 1998; Suzuki and Sugiyama, 1999). MRP3 also has the capacity to 
transport organic anionic drugs and glucuronate-conjugated drugs, as well as a wide 
range of bile salts such as glycocholate, taurolithocholate-3-sulfate, and 
taurochenodeoxycholate-3-sulfate (Hirohashi et al., 2000; Zeng et al., 2000; Zelcer 
et al., 2001). Substrates for MRP4 include folic acid, folinic acid (Chen et al., 2002) 
and thiopurines (Wielinga et al., 2002). MRP5 has an affinity for nucleotide-based 
substrates including anticancer thiopurine and thioguanine drugs (Wijnholds et al., 
2000; Wielinga et al., 2002; Reid et al., 2003). Organic anion such as 
benzbromarone and sulfinpyrazone inhibit MRP5 (Wijnholds et al., 2000). MRP6 is 
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involved in the transport of agents such as etoposide, doxorubicin, and cisplatin in 
Chinese hamster ovary cells (Belinsky et al., 2002), while MRP7 transports 
docotaxel and 17β-estradiol-(17β-D-glucuronide) (Hopper-Borge et al., 2004). 
MRP8 has been reported to mediate the efflux of cyclic nucleotides (Guo et al., 
2003). 
 
1.4.1 (c) Breast Cancer Resistance Protein (BCRP; ABCG2) 
Human BCRP encodes a 655 amino acid ABC protein, containing a single N-
terminal ATP binding cassette, followed by 6 putative transmembrane segments. 
Based on structural and sequence homology, BCRP belongs to the ABCG gene 
family, containing amongst others the Drosophila white, brown, and scarlet protein 
genes, the human white homologue ABCG1, and the more recently identified genes 
ABCG5 and ABCG8. BCRP was therefore renamed ABCG2 (Berge et al., 2000; Lee 
et al., 2001). 
 
 
BCRP is expressed in the apical side of small intestine, colon, liver, placenta and 
ovary (Scheffer et al., 2000; Maliepaard et al., 2001). Some of the substrates of this 
pump include methotrexate (Sarkadi et al., 2004), camptothecins (Sarkadi et al., 
2004), and estrone 3-sulfate (Leslie et al., 2005), while the inhibitors are tamoxifen 
and novobiocin (Staud and Pavek, 2005). 
 
1.4.1 (d) Proton/Oligopeptide Transporters (POT; SLC15A)  
Peptides like agents are widely used in the treatment of many disorders including 
AIDS, hypertension, and cancer. To date peptide transporters that are reported 
include the Peptide Transporters 1 and 2, PepT1 (SLC15A1) and PepT2 (SLC15A2); 
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the Peptide/Histidine Transporters 1 and 2, PHT1 (SLC15A4) and PHT2 
(SLC15A3); and the Intestinal Peptide Transporter PT1 (CDH17) (Fei et al., 1998; 
Meredith and Boyd, 2000).  
 
PepT1 protein was found to be expressed in the human small intestine (Liang et al., 
1995; Herrera-Ruiz et al., 2001) and is localized on the apical plasma membrane of 
enterocytes in rats (Ogihara et al., 1999).  
 
Two human peptide/histidine (hPHT) transporters have been recognized (Botka et 
al., 2000; Knipp and Herrera-Ruiz, 2003). Both hPHT1 and hPHT2 have reported to 
be expressed along the entire GI tract, especially in the small intestine and colon 
(Herrera-Ruiz et al., 2001). Some of the substrates of peptide transporters are 
cefatrizine, cefepine, cefixime, cloxacillin, cyclacillin, valaciclovir, and 
valganciclovir while the inhibitors are latamoxef, enalaprilate and fosinoprilate 
(Bhardwaj et al., 2006). 
 
1.4.1 (e) Organic Anion Transporters (OAT, SLC22A; OATP, SLCO) 
It has been reported that intestinal absorption of various ionized drugs is mediated by 
the organic anion (OA) or organic cation (OC) transporter systems (Katsura and Inui, 
2003; Sai and Tsuji, 2004; Steffansen et al., 2004). 
 
The organic anion transporters are classified as organic anion transporters (OATs), 
organic anion transporting polypeptides (rodents: Oatps; human: OATPs) and 
multiple drug resistance-associated proteins (MRPs) (Hagenbuch and Meier, 2003; 
Van Montfoort et al., 2003; Koepsell and Endou, 2004).  
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OATP/Oatp members mediate the transport of organic anions and other compounds 
in a Na+-independent manner (Tirona and Kim, 2003; Hagenbuch and Meier, 2003; 
Van Montfoort et al., 2003). Glutathione (GSH) plays a significant role in rat Oatp1 
and Oatp2 (Li et al., 1998; Li et al., 2000) substrate transport. A proton-coupled 
transport mechanism has also been suggested for OATP/Oatp isoforms (Kobayashi et 
al., 2003). OATP/Oatp family members (e.g., OATP-B, OATP-D, and OATP-E) are 
expressed in blood-brain barrier (BBB), lung, heart, kidney, placenta, and intestine 
(Hagenbuch and Meier, 2003; Kim, 2003; Van Montfoort et al., 2003). 
 
 
1.4.1 (f) Organic Cation Transporters (OCT, OCTN; SLC22A) 
Generally most of the organic cations are polar and positively charged at 
physiological pH, membrane bound transporters are essential to enhance their 
intestinal permeability. Organic cation transporter 1 (OCT1) was the first of the OC 
family transporter that was identified (Grundemann et al., 1994). Subsequently, other 
organic cation transporters (OCT2–3), carnitine and organic cation transporters 
(OCTN1–3) have been identified (Koepsell et al., 2003; Koepsell and Endou, 2004; 
You, 2004). Tetraethylammonium and N-methylquinine, acyclovir, ganciclovir, 
metformin and phenformin, memantine and quinidine are few of the drugs that are 
reported to be transported by various organic cationic transporters (Koepsell et al., 
2003; Koepsell and Endou, 2004; You, 2004).  
 
OCTs transport organic cations and other compounds in an electrogenic manner, for 
the rat isoforms rOCT1, rOCT2, and rOCT3 (Busch et al., 1996; Nagel et al., 1997; 
Kekuda et al., 1998; Okuda et al., 1999), and for the human transporters hOCT1 and 
hOCT2 (Gorboulev et al., 1997; Busch et al., 1998). In addition, OCTs mediated 
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transport is independent from Na+ and H+ ions (Busch et al., 1996; Gorboulev et al., 
1997; Kekuda et al., 1998). Driving force for substrate transport is provided by the 
substrate concentration gradient and the membrane potential (Busch et al., 1996; 
Gorboulev et al., 1997; Busch et al., 1998; Kekuda et al., 1998; Okuda et al., 1999). 
OCT isoforms are mainly expressed in the liver and kidney, and to a less extent, in 
the heart, skeletal muscle, placenta, and small intestine. hOCT1 is mainly expressed 
in the liver, whereas hOCT2 is mainly found in the kidney (Gorboulev et al., 1997).  
hOCTN1 and hOCTN2 are both expressed abundantly in the kidney, skeletal muscle, 
placenta, prostate, and heart (Tamai et al., 1997; Tamai et al., 1998; Wu et al., 1999), 
with hOCTN2 also being expressed at low level in the liver (Tamai et al., 1998). 
rOCTN1 is present principally in the liver (Wu et al., 2000). 
 
1.4.1 (g) Nucleoside Transporters (CNT, SLC28A; ENT, SLC29A) 
The cellular transport of nucleosides is mediated by two distinct families of 
transporter proteins: the high affinity, concentrative nucleoside transporters (CNT; 
SLC28) and the low affinity, equilibrate nucleoside transporters (ENT; SLC29). The 
SLC28 family is sodium dependent and works through an active transport 
mechanism, while the SLC29 family functions by a facilitated diffusion mechanism. 
The human SLC28 family consists of three subtypes of sodium-dependent, 
concentrative nucleoside transporters, hCNT1 (SLC28A1), hCNT2 (SLC28A2); also 
termed SPNT for sodium-dependent purine nucleoside transporter, and hCNT3 
(SLC28A3). The human SLC29 transporter family contains four members, hENT1 
(SLC29A1), hENT2 (SLC29A2), hENT3 (SLC29A3), and hENT4 (SLC29A4) (Gray 
et al., 2004). 
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